Transsphenoidal pituitary resection for preoperative diagnosis of prolactin-secreting pituitary adenoma in women: long term follow-up.
The long term efficacy and safety of transsphenoidal resection for preoperative diagnosis of PRL-secreting pituitary adenomas in a large series of women have not been described. Four hundred and nine consecutive women at this university tertiary referral center undergoing transsphenoidal resection for preoperative diagnosis of PRL-secreting pituitary adenoma were followed for a minimum of 4 yr. The objective was to determine the efficacy and morbidity of this procedure and to identify features correlating with the resolution of hyperprolactinemia. Outcome measures included referral, preoperative, surgical, postoperative hospitalization, and long-term follow-up information, including recent PRL concentration. Follow-up was ascertained in 83% of patients who were followed for a mean of 9.2 yr. Recurrence of hyperprolactinemia occurred in 47% of total patients, but in only 16% with a single surgical procedure, histological diagnosis of prolactinoma, and postoperative PRL concentration of 5 ng/mL or less. The best single predictor of cure was postoperative day 1 PRL concentration of 5 ng/mL or less. Eighty-eight percent of women desiring conception conceived within 1 yr. Glucocorticoid-dependent hypopituitarism occurred in 23% of patients undergoing postoperative radiotherapy. There was no operative mortality. Operative morbidity was low. Our experience demonstrates that women undergoing transsphenoidal surgery for diagnosis of PRL-secreting adenoma form a heterogeneous patient population. The best long term results are achieved in the pure prolactinoma group, for whom transsphenoidal resection is generally safe and effective.
Feigenbaum
S L
SL
Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco 94143, USA.
Downey
D E
DE
Wilson
C B
CB
Jaffe
R B
RB
D000293:Adolescent; D000328:Adult; D000368:Aged; D000568:Amenorrhea; D001971:Bromocriptine / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D013006:Growth Hormone / Q000032:analysis / Q000378:metabolism; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D010902:Pituitary Gland / Q000503:physiopathology; D010911:Pituitary Neoplasms / Q000473:pathology* / Q000503:physiopathology / Q000601:surgery*; D011247:Pregnancy; D011256:Pregnancy Outcome; D015175:Prolactinoma / Q000473:pathology* / Q000503:physiopathology / Q000601:surgery*; D012086:Reoperation
D001971:Bromocriptine; D013006:Growth Hormone